Quick Answer
FibroBiologics, Inc. reported Cash and Equivalents of $4.89 million for fiscal year 2025.
FibroBiologics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.89M | -65.0% |
| 2024 | $13.98M | +52.6% |
| 2023 | $9.16M | +304.4% |
| 2022 | $2.27M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $4.87M | -37.8% | -45.0% |
| June 30, 2025 | $8.85M | +48.1% | +2.1% |
| March 31, 2025 | $8.67M | +6.2% | -38.0% |
| December 31, 2024 | $13.98M | +52.6% | +78.7% |
| September 30, 2024 | $7.83M | — | +31.0% |
| June 30, 2024 | $5.97M | — | -26.8% |
| March 31, 2024 | $8.16M | — | -11.0% |
| December 31, 2023 | $9.16M | — | — |
- FibroBiologics, Inc. showed a decrease of -65.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2022–2025 period, FibroBiologics, Inc.’s cash and equivalents has grown by 116.0% (from $2.27 million to $4.89 million).
- The most recent figure is from FibroBiologics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: